Status:
COMPLETED
Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia
Lead Sponsor:
National Institute of Mental Health and Neuro Sciences, India
Conditions:
Schizophrenia
Negative Symptoms
Eligibility:
All Genders
17-50 years
Phase:
PHASE4
Brief Summary
Negative symptoms in schizophrenia present a challenge to the clinician owing to their poorer response to conventional treatment with antipsychotics. Negative symptoms in schizophrenia may be secondar...
Eligibility Criteria
Inclusion
- Patients fulfilling DSMIV Criteria for Schizophrenia
- The patient should be drug naïve or drug free for one month (oral antipsychotic) or three months of parental antipsychotic
- Duration from onset \< 5 years
- Informed consent
Exclusion
- Patient with any other current Axis I or Axis II comorbid disorders
- Comorbid substance abuse or dependence except nicotine or caffeine
- Presence of significant medical disorder such as epilepsy, uncontrolled hypertension and diabetes mellitus, thyroid disorder
- Patient who has not responded to adequate course of risperidone (with reference to dose and duration)
- Treatment-resistant schizophrenia defined as non-response to three different antipsychotics belonging to at least two different classes, one of which is an atypical agent and one of which is a depot neuroleptic
- Patient who has received ECT in past 3 months
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00893256
Start Date
December 1 2004
End Date
September 1 2007
Last Update
May 5 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Mental Health and Neurosciences (NIMHANS)
Bangalore, Karnataka, India, 560 029